Q3 FY26 Results: Revenue up 7%, but standalone and consolidated PAT in loss

Going ConcernEmphasis Of MatterPat NegativeExceptional ItemResults View source PDF Explain this filing

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+10.2%Reaction day

₹213.30

prior close

₹237.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+3.7%+6.5% vs market

Pharmaceuticals peers, median of 157sector+2.6%+7.6% vs sector

On the reaction day the stock moved 6.5 pts more than Nifty Microcap 250 and 7.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.2

10m

-2.0

15m

-1.7

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+10.2+3.7+6.5+2.6+7.6

Next day

+5.7+5.1+0.6+2.5+3.2

+4.5+4.0+0.5+1.6+2.9

-1.0+3.2-4.2+1.2-2.3

-3.4+5.9-9.3+2.9-6.3

-1.9+6.9-8.9+3.6-5.5

-4.4+5.9-10.2+2.6-6.9

15d

-3.4+2.1-5.5-0.6-2.8

-6.7-3.5-3.2-2.6-4.1

-10.7-4.2-6.4-4.7-6.0

-0.6+10.9-11.5+4.2-4.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indoco Remedies reported Q3 FY26 standalone revenue of Rs. 389.6 cr, up 7% YoY. However, standalone PAT swung to a loss of Rs. 20 cr vs a loss of Rs. 10.2 cr a year ago. 9M FY26 standalone PAT is a loss of Rs. 33 cr against a profit of Rs. 17.5 cr last year. Consolidated 9M PAT shows a loss of Rs. 75 cr. Exceptional items include Rs. 6.9 cr impact from new Labour Codes. Auditor flagged going concern uncertainty for two subsidiaries.

Likely market impact

Mixed picture. Top line grew but profitability worsened sharply. Going concern flag on two subsidiaries is a key risk watch item.